In the first session of our 2020 webinar series, we discussed the key responses to the COVID-19 pandemic in Europe and the United States that impact biologics and biosimilars.
Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, they are facing a great deal of uncertainty due to ever-changing emergency policies aimed at addressing COVID-19.
In this session we focussed on critical developments impacting biologic and biosimilar companies, including:
What activity do they cover?